SOURCE: Cardima, Inc.

January 31, 2007 09:00 ET

Cardima to Host Scientific Symposium at the CardioRhythm 2007 Conference in Hong Kong on Sunday, February 4th, 2007

FREMONT, CA -- (MARKET WIRE) -- January 31, 2007 -- Cardima, Inc. (OTCBB: CRDM), developer of the REVELATION® Tx, REVELATION® T-Flex and REVELATION® Helix ablation microcatheters and INTELLITEMP® Energy Management Device, will host a luncheon symposium at the CardioRhythm 2007 Conference to be held at the Hong Kong Convention and Exhibition Center from February 2nd-4th, 2007. Cardima's symposium will showcase the most recent developments in atrial fibrillation (AF) treatment using the REVELATION® family of microcatheters. Approximately 1,500 physicians, medical professionals and industry representatives from the Asian-Pacific region are expected to attend the CardioRhythm conference this year.

Cardima's luncheon symposium, entitled "New System and Techniques for Catheter-Based Treatment of Atrial Fibrillation," will be held on Sunday, February 4th, 2007 at 12:00 p.m. The symposium panel will be chaired by Sung Chun, M.D., Director of Cardiac Electrophysiology, Palo Alto Medical Foundation, California. The other panelist is Jaswinder Gill, MBBChir, MD, FRCP, Director of Pacing and Electrophysiology at Guy's and St. Thomas' Hospitals, London.

"We are proud to present the INTELLITEMP®-controlled ablation experiences with the REVELATION® T-Flex and REVELATION® Helix catheters at the CardioRhythm conference," stated Gabriel Vegh, Chief Executive Officer of Cardima.

According to Dr. Eric Chan, Senior Vice President of Product Development of Cardima, "Dr. Chun will discuss the effectiveness of our linear electrode technology as incorporated into our REVELATION® series of catheters and show atrial lesion histology from animal studies performed at Stanford University Medical Center. In addition, Dr. Gill will present his most recent clinical experiences with the REVELATION® T-Flex as an efficacious and faster alternative to other existing ablation procedures for the treatment of atrial fibrillation."

About Atrial Fibrillation (AF)

AF, described as a rapid and chaotic quivering of the top two chambers in the heart, is the most prevalent arrhythmia, affecting more than two million patients in the U.S., with an annual incidence of 160,000 new cases per year. AF is a leading cause of stroke and hospitalizations, and has become the most common complication of cardiovascular surgery. If left untreated, it can lead to heart failure and death.

About Cardima, Inc.

Since our incorporation in November 1992, we have developed, produced and sold a variety of microcatheters designed for the diagnosis and treatment of the two most common forms of cardiac arrhythmias: atrial fibrillation (AF) and ventricular tachycardia (VT). Since 2001 our efforts have primarily focused on developing differentiated products that diagnose and treat AF, including our REVELATION® Tx microcatheter for use in the Electrophysiology (EP) market, and our Surgical Ablation System (SAS) for use in the surgical market.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties are set forth in the Company's filings with the Securities & Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information